James Zangrilli, MD

Contact Dr. Zangrilli

834 Walnut Street
Ste. 650
Philadelphia, PA 19107

(215) 955-5161
(215) 923-6003 (fax)

Medical School
Jefferson Medical College - 1988

Residency
Thomas Jefferson University Hospital 1989 - 1991

Fellowship
Thomas Jefferson University Hospital 1991 - 1995

Board Certification
Pulmonary Disease
Critical Care Medicine
Internal Medicine

Hospital Appointment
Thomas Jefferson University Hospital

University Appointment
Assistant Professor of Medicine, 1996

Research and Clinical Interests
Dr. Zangrilli has been and remains active within the Division of Pulmonary and Critical Care at Thomas Jefferson University Hospital. He has a part-time appointment in the Pulmonary Critical Care Division where he sees outpatients, mentors fellows' clinic, and where he participates actively in several educational programs. His primary role is director, clinical research, respiratory and inflammation therapeutic area, AstraZeneca, Wilmington, Delaware.

Dr. Zangrilli graduated from Jefferson Medical College in 1988. He subsequently completed a 3-year residency training program at Thomas Jefferson University Hospital. This was followed by a 3-year fellowship in Pulmonary and Critical Care Medicine also at Thomas Jefferson University Hospital. In addition, he completed a year as a research fellow, followed by a year as a research associate also at Thomas Jefferson University. He has been an assistant professor since 1996 until his departure to industry in 2008. Dr. Zangrilli was the director of the Pulmonary/Critical Care Fellowship Program at Jefferson between 1999 and 2008, and he had successful re-accreditations for the ACGME Fellowship Program.

Dr. Zangrilli was productive on the tenure-track faculty while at Jefferson. He received several pilot awards including the Allen & Hansbury Pulmonary Fellowship in 1994 ($30,000 to study connective tissue regulation by immune cells from the asthmatic lung); Merck Young Investigators' Award in 1994; NIH Training Grant for program in Biomolecular Signal Transduction (program director was Gerald Litwack); received the American Lung Association Research Grant to study molecular mechanisms of eosinophil apoptosis ($25,000 a year). He was a co-investigator on several asthma related grants between 1986 and 2003. He was a principal investigator on an NIH K08 award from 1998 through 2004 for mechanisms of programmed cell death in eosinophils. He subsequently received an NIH RO1 between December 2004 and November 2009 where Dr. Zangrilli was a PI, for regulation of inflammation and asthma by Fas Ligand. Dr. Zangrilli lists 26 original peer-reviewed publications including 5 as a first author, including 3 publications in the past 12 months. In addition, he lists 10 book chapters and a variety of case reports and abstracts as well. Since transitioning to industry, Dr. Zangrilli has been the clinical lead on a phase II kinase inhibitor for asthma as well as several other emerging products for asthma.

Publications

Most recent Peer-reviewed Publications

1. Systemic FasL neutralization increases eosinophilic inflammation in a mouse model of asthma
2. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: A randomized, controlled trial
3. Ozone inhalation induces exacerbation of eosinophilic airway inflammation and hyperresponsiveness in allergen-sensitized mice
4. Decades Later, A New Complication
5. Bid activation during induction of extrinsic and intrinsic apoptosis in eosinophils
6. Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: Associations with asthmatic phenotype, airway inflammation and β2-agoinst use
7. TRAIL in the Airways
8. Left ventricular intracardiac metastatic germ cell tumor presenting with hemorrhagic cerebrovascular event
9. Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-β1, TGF-β2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on α-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts
10. Concentration of cytokines and growth factors in BAL fluid after allergen challenge in asthmatics and their effect on α-smooth muscle actin and collagen III synthesis by human lung fibroblasts
11. Modulation of vasodilator-stimulated phosphoprotein in vivo in human epithelial cells by segmental allergen challenge and β2-agonist therapy
12. Overlap between death receptor and non-receptor-mediated mechanisms during apoptosis in human eosinophils
13. Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: Evidence for a role of TRAIL in eosinophil survival
14. Atypical mycobacterial osteomyelitis in a non-AIDS patient
15. Distinction between IL-13+ and IFN-γ+ natural killer cells and regulation of their pool size by IL-4
16. Asthmatic epithelial cell proliferation and stimulation of collagen production: Human asthmatic epithelial cells stimulate collagen type III production by human lung myofibroblasts after segmental allergen challenge
17. Regulation of eosinophil viability by cytokines
18. Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects
19. Effect of IL-5, glucocorticoid, and Fas ligation on Bcl-2 homologue expression and caspase activation in circulating human eosinophils
20. HSP27 elevated in mild allergic inflammation protects airway epithelium from H2SO4 effects

View All Publications